Strategic funding Acrigen secured seed funding in 2021 from Red Tree Venture Capital with participation from multiple biotech investors, signaling investor confidence and potential for a follow-on round. This presents an opportunity to engage with the leadership on partnership or funding milestones aligned to their clinical ambitions.

Leadership & governance New board member appointment by Red Tree Venture Capital in 2021 brings experienced biosciences governance and venture oversight. Leverage this to propose strategic collaborations, joint research programs, or advisory partnerships that align with their precision gene editing roadmap.

Technology edge Acrigen combines CRISPR-Cas editors with anti-CRISPR proteins to enhance precision and safety in gene therapies. This unique tech focus opens opportunities to discuss complementary tools, delivery platforms, analytics, and regulatory-grade validation services that support their pipeline milestones.

Early-stage growth With a small team and revenue in the low single digits, Acrigen is in a critical development phase likely seeking specialized CRO, manufacturing, or regulatory support partners. This is a chance to offer scalable, flexible services that match their budget constraints and timeline.

Location and network Berkeley, California positioning and connections to UCSF leadership (co-founder is a UCSF associate professor) indicate a strong academic-to-industry bridge. Target collaborations around academic partnerships, translational studies, and access to university-affiliated resources or grant opportunities.